Alk Knockout mouse models

Anaplastic lymphoma kinase is encoded by Alk, the mouse ortholog of human ALK, a single-pass receptor tyrosine kinase of the insulin receptor superfamily whose extracellular MAM, LDLa, and glycine-rich domains bind the ALKAL1 and ALKAL2 ligands to drive dimerization and trans-autophosphorylation, feeding RAS/MAPK, PI3K/AKT, and JAK/STAT3 output. Oncogenic activation follows two distinct routes: chromosomal fusions such as EML4-ALK and NPM1-ALK that impose ligand-independent oligomerization, and kinase domain substitutions including F1174L and R1275Q found in neuroblastoma. Allele choice should follow the question, since an inducible fusion knockin at the Alk locus interrogates fusion-driven lung or lymphoid tumorigenesis, a point-mutant knockin reproduces neuroblastoma predisposition, and ectodomain humanization supports antibody, conjugate, and CAR-T pharmacology alongside resistance modeling for L1196M or G1202R. Because Alk null animals are viable with only subtle neurobehavioral changes, constitutive nulls suit ligand-axis studies, while tumor endpoints demand a tissue-restricted Cre or inducible expression matched to the target lineage.

Alk null animals are straightforward to genotype and phenotype when survival is acceptable. They remain a standard background for pharmacology, biomarker, and rescue studies.